Pomeranian Medical University in Szczecin will implement a project entitled “Evaluation of the efficacy and safety of berubicin in the treatment of central nervous system lymphomas”. The amount of funding from the Medical Research Agency is PLN 8.5 million.

Berubicin is a modern anthracycline drug with unique properties of penetrating the blood-brain barrier. In addition, it is characterized by little dependence on the activity of multidrug resistance proteins, which are largely responsible for the ineffectiveness of conventional chemotherapy.

The aim of the project is a single-arm, non-randomized, open label clinical trial on the use of berubicin in the treatment of patients with primary and secondary lymphomas of the central nervous system. The research will be carried out in close cooperation with the MD Anderson Cancer Center in the USA – one of the largest cancer centers in the world.